🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is — my results so far Page 3

Can we talk about how SLOW the FDA is — my results so far

NurseAsh_DET Tue, Nov 18, 2025 at 7:47 PM 43 replies 1,294 viewsPage 3 of 9
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Nov 21, 2025 at 3:36 PM#11
PharmacoVig_BOS said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

Last edited: Nov 21, 2025 at 9:36 PM
50 23kim_atl_prep, sarah_TO, wendy_avl and 47 others
Reply Quote Save Share Report
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Nov 23, 2025 at 5:57 AM#12
jason_paloalto said:
DebRD_ATL said: ...regarding the trial evidence...

Bookmarking. The distinction being drawn above is the one nobody else makes.

Last edited: Nov 23, 2025 at 11:57 AM
1 24LibrarianMeg
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Nov 24, 2025 at 8:16 PM#13
PharmacoVig_BOS said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

I read this differently from PharmacoVig_BOS, on substance rather than tone. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

Ask again with the specifics and you will get a better answer than this one.

2 0DadBodDave, AmyNC_wife
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Nov 26, 2025 at 10:34 AM#14

One concrete data point for the thread. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

Last edited: Nov 26, 2025 at 11:34 AM
3 1james_edin, FranDenver, Dr.BariatricHTX
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 28, 2025 at 12:52 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out.

4 2PurityPaulOR, MaxMetOK, MounjBrad and 1 other
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register